John A. Jakob

John A. Jakob

Auto-generated profile, based on publicly available information

John A. Jakob

Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center; Houston Texas

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2014 in Head & Neck
Verified
Journal Article
Open access
PDF file
JJJohn A. Jakob
John A. Jakob
MKMerrill S. Kies
Merrill S. Kies
BGBonnie S. Glisson
Bonnie S. Glisson
MKMichael E. Kupferman
Michael E. Kupferman
DLDiane D. Liu
Diane D. Liu
GBGeorge R. Blumenschein
George R. Blumenschein
Background The purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. Methods We conducted a phase II study in adenoid cystic carcinoma (ACC) and non‐ACC. Gefitinib was administered 250 mg orally daily. The primary endpoint was tumor response. Secondary endpoints included progression‐free survival (PFS), overall survival (OS), and disease control rates. EGFR and human epidermal growth factor receptor 2 (HER2) expression were evaluated and correlated with outcomes. Results Thirty‐seven patients were enrolled in this study, and 36 were evaluable (18 with ACC and 18 with non‐ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non‐ACC, respectively. The disease control rate at 8 weeks was higher in patients with ACC. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. Conclusion We did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002. © 2015 Wiley Periodicals, Inc. Head Neck 37: 644–649, 2015